N-(4-chlorobenzyl)-2-phenylquinazolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(4-chlorobenzyl)-2-phenylquinazolin-4-amine
• 英文别名: (4-chlorobenzyl)-(2-phenylquinazolin-4-yl)-amine；N-[(4-chlorophenyl)methyl]-2-phenylquinazolin-4-amine
• 化学式: C₂₁H₁₆ClN₃
• 分子量: 345.831
• InChiKey: SXMZJRHVNMVEAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-苯基-4-[3H]喹唑啉酮 在 五氯化磷 、 potassium carbonate 、 三氯氧磷 作用下， 以 丙酮 为溶剂， 反应 5.0h， 生成 N-(4-chlorobenzyl)-2-phenylquinazolin-4-amine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents

  摘要：

  Twenty-two quinazoline derivatives have been synthesised and examined for their anti-tumour activity against three tumour cell lines, namely human breast cancer cell line (MCF-7), human cervical cancer cell line (HeLa) and human hepatoma cell line (HepG2). Twelve of the tested compounds have shown promising anti-tumour activity with an IC50 range of 5.0-9.7 mu g/mL. Regarding the spectrum of activity, five compounds exhibited interesting anti-proliferative properties against the three tested cell lines comparable to the reference drug (dasatinib).

  DOI：

  10.3109/14756366.2011.601302

文献信息

• Synthesis, 2D-QSAR Studies and Biological Evaluation of Quinazoline Derivatives as Potent Anti-Trypanosoma cruzi Agents
  作者：Mariela Bollini、Ana M. Bruno、María E. Niño、Juan J. Casal、Leandro D. Sasiambarrena、Damián A.G. Valdez、Leandro Battini、Vanesa R. Puente、María E. Lombardo

  DOI：10.2174/1573406414666181005145042

  日期：2019.4.12

  disease. Therefore, continuous research is an urgent need so as to discover novel therapeutic alternatives. Objective: The development of safer and more efficient therapeutic anti-T. cruzi drugs continues to be a major goal in trypanocidal chemotherapy. Method: Synthesis, 2D-QSAR and drug-like physicochemical properties of a set of quinazolinone and quinazoline derivatives were studied as trypanocidal

  背景：恰加斯病感染了全世界约700万人。目前只有两种药物可用于治疗这种寄生虫病，即苯并尼达唑（Bzn）和硝呋替莫（Nfx）。两种药物在该疾病的慢性期均具有有限的疗效。因此，持续的研究是迫切需要以发现新颖的治疗选择。 目的：开发更安全，更有效的治疗性抗-T。Cruzi药物仍然是锥虫杀伤性化疗的主要目标。 方法：研究了一组喹唑啉酮和喹唑啉衍生物作为锥虫杀螨剂的合成，2D-QSAR和类药物理化性质。体外针对克氏锥虫（图拉胡恩（Tulahuen）菌株，Tul 2原种）的表鞭毛纲动物和血流类锥鞭毛纲动物筛选了所有化合物。 结果：在合成和测试的34种化合物中，有6种化合物（5a，5b，9b，9h，13f和13p）对前鞭毛体和三鞭毛体均显示出显着活性，而对Vero细胞无毒性。 结论：这些喹唑啉酮和喹唑啉衍生物的抗原生动物活性代表了针对旨在开发查加斯病的新型化学疗法的药物化学程序的有趣起点。
• QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY
  申请人：Lee Nam Kyu

  公开号：US20080207614A1

  公开（公告）日：2008-08-28

  The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient.

  本发明涉及一种新型喹唑啉衍生物，能够有效降低血糖水平和体重，以及一种用于治疗和/或预防糖尿病和/或肥胖的药物，其中该化合物作为活性成分。
• 糖尿及び肥満治療予防に有効なキナゾリン誘導体
  申请人：エスケー ケミカルズ カンパニー リミテッド

  公开号：JP2008526734A

  公开（公告）日：2008-07-24

  本発明は血糖降下、体重減少を現わす新規のキナゾリン誘導体と、この化合物を有効成分として含む糖尿及び肥満治療予防剤に関する。【選択図】図１

  本发明涉及一种新型喹唑啉衍生物，该衍生物具有降血糖和减轻体重的作用，还涉及一种含有该化合物作为活性成分的糖尿病和肥胖症治疗和预防剂。[选图] 图 1.
• Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
  作者：Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani

  DOI：10.1021/jm00018a014

  日期：1995.9

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.
• METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE
  申请人：California Institute of Technology

  公开号：EP2566480A2

  公开（公告）日：2013-03-13